Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1

21 Feb 2014

Abstract excerpt

Inhibitors of the mechanistic target of rapamycin (mTOR) hold promise for treatment of hematological malignancies. Analogs of the allosteric mTOR inhibitor rapamycin are approved for mantle cell lymphoma but have limited efficacy in other blood cancers. ATP-competitive "active-site" mTOR inhibitors produce more complete mTOR inhibition and are more effective than rapamycin in preclinical models of leukemia,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chronic Lymphocytic Leukemia Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24586420
DOI: 10.1371/journal.pone.0088865

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance to mTOR Kinase Inhibitors in Lymphoma Cells Lacking 4EBP1PMID 24586420Read ↗

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.Semantic proximity Read ↗

Control of translational activation by PIM kinase in activated B-cell diffuse large B-cell lymphoma confers sensitivity to inhibition by PIM447.Semantic proximity Read ↗

PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axisSemantic proximity Read ↗

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapySemantic proximity Read ↗

Targeting mTOR in Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?Semantic proximity Read ↗

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1Semantic proximity Read ↗

A kinase-independent role for CDK8 in BCR-ABL1+ leukemiaSemantic proximity Read ↗

mTOR: Role in cancer, metastasis and drug resistanceSemantic proximity Read ↗

ETV7 is an essential component of a rapamycin-insensitive mTOR complex in cancerSemantic proximity Read ↗

Targeting the mTORC2 signaling complex in B cell malignanciesSemantic proximity Read ↗

Reversing Drug Resistance In VivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.